Rock Springs Capital Management’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q3
Sell
-2,306,196
Closed -$41.5M 162
2020
Q2
$41.5M Buy
2,306,196
+554,296
+32% +$7.71M 1.14% 29
2020
Q1
$12.5M Buy
1,751,900
+851,900
+95% +$10.6M 0.52% 64
2019
Q4
$21.5M Sell
900,000
-150,000
-14% -$4.14M 0.68% 58
2019
Q3
$28.2M Buy
1,050,000
+42,000
+4% +$1.18M 1.12% 27
2019
Q2
$27.3M Buy
1,008,000
+133,000
+15% +$4.17M 0.99% 34
2019
Q1
$30.4M Buy
875,000
+575,000
+192% +$16.6M 1.17% 23
2018
Q4
$5.86M Sell
300,000
-23,800
-7% -$489K 0.28% 91
2018
Q3
$8.62M Hold
323,800
0.31% 92
2018
Q2
$12.2M Hold
323,800
0.47% 73
2018
Q1
$10.6M Hold
323,800
0.45% 76
2017
Q4
$15.8M Hold
323,800
0.72% 49
2017
Q3
$17.5M Buy
323,800
+184,100
+132% +$10.8M 0.81% 46
2017
Q2
$7.85M Buy
+139,700
New +$5.6M 0.4% 77
2016
Q3
Sell
-175,000
Closed -$4.13M 145
2016
Q2
$4.13M Hold
175,000
0.31% 90
2016
Q1
$3.57M Buy
175,000
+10,000
+6% +$317K 0.3% 94
2015
Q4
$8.49M Buy
+165,000
New +$8M 0.64% 56

Rock Springs Capital Management's PTLA Position: Q3 2020 in Review

Rock Springs Capital Management sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q3 2020, closing a stake of 2,306,196 shares — an estimated $41.5M sold.

Rock Springs Capital Management first reported a position in PTLA in Q4 2015 and held it in 16 quarters. The position peaked at $41.5M in Q2 2020. 0 funds tracked by Wall St. Rank hold PTLA as of Q3 2020.

  • Rock Springs Capital Management reported no remaining Portola Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
  • Rock Springs Capital Management sold 2,306,196 Portola Pharmaceuticals, Inc. shares in Q3 2020, an estimated $41.5M.
  • Rock Springs Capital Management first reported a position in Portola Pharmaceuticals, Inc. in Q4 2015 and held it in 16 quarters.
  • Rock Springs Capital Management's Portola Pharmaceuticals, Inc. position peaked at $41.5M in Q2 2020.
  • 0 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q3 2020.

Based on Rock Springs Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.